A 52-week Randomized Safety Study of a Calcipotriol/betamethasone Dipropionate Two-compound Product (Dovobet/Daivobet/Taclonex) in the Treatment of Psoriasis Vulgaris
Overview
Authors
Affiliations
Background: The calcipotriol/betamethasone dipropionate two-compound product Dovobet/Daivobet/Taclonex(LEO Pharma A/S, Ballerup, Denmark) has been shown to be safe and effective in the treatment of psoriasis for up to 8 weeks. As psoriasis is a chronic disease, long-term treatment may be required, so there is a need to investigate the safety of its use over a longer period of time.
Objectives: To investigate the safety of two treatment regimens involving use of the two-compound product over 52 weeks in the treatment of patients with psoriasis.
Methods: Patients (n = 634) were randomized double-blind to treatment with: (i) 52 weeks of the two-compound product (two-compound group); (ii) 52 weeks of alternating 4-week periods of the two-compound product and calcipotriol (alternating group); or (iii) 4 weeks of the two-compound product followed by 48 weeks of calcipotriol (calcipotriol group). Treatments in all groups were used once daily when required.
Results: Adverse drug reactions (ADRs) occurred in 45 (21.7%) patients in the two-compound group, 63 (29.6%) in the alternating group and 78 (37.9%) in the calcipotriol group. The odds ratio for an ADR in the two-compound group relative to the calcipotriol group was 0.46 (95% confidence interval 0.30-0.70; P < 0.001). ADRs of concern associated with long-term topical corticosteroid use occurred in 10 (4.8%) patients in the two-compound group, six (2.8%) in the alternating group and six (2.9%) in the calcipotriol group; those with the highest incidence were skin atrophy, occurring in four (1.9%), one (0.5%) and two (1.0%) patients, respectively, and folliculitis, in three (1.4%), one (0.5%) and no patients, respectively.
Conclusions: Treatment with the two-compound product for up to 52 weeks appears to be safe and well tolerated whether used on its own or alternating every 4 weeks with calcipotriol treatment.
Kedra K, Reich A Drug Des Devel Ther. 2024; 18:5827-5839.
PMID: 39670279 PMC: 11636291. DOI: 10.2147/DDDT.S240867.
Fargnoli M, De Simone C, Gisondi P, Pellacani G, Calzavara-Pinton P Dermatol Ther (Heidelb). 2023; 13(11):2527-2547.
PMID: 37737941 PMC: 10613180. DOI: 10.1007/s13555-023-01024-9.
Hong J, Wu P, Qin A, Huang Y, Tseng K, Lai C Pharmaceutics. 2022; 14(10).
PMID: 36297594 PMC: 9608911. DOI: 10.3390/pharmaceutics14102159.
Narbutt J, Czajkowski R, Lesiak A, Owczarek W, Reich A, Szepietowski J Postepy Dermatol Alergol. 2021; 38(5):727-733.
PMID: 34849116 PMC: 8610051. DOI: 10.5114/ada.2021.110062.
Emerging paradigm shift toward proactive topical treatment of psoriasis: A narrative review.
Papp K, Dhadwal G, Gooderham M, Guenther L, Turchin I, Wiseman M Dermatol Ther. 2021; 34(6):e15104.
PMID: 34418251 PMC: 9286633. DOI: 10.1111/dth.15104.